title: A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
abstract: A blind performance test was conducted to evaluate dose-calibrator measurements at nuclear pharmacies in the United States (US). Two test-sample geometries were chosen to represent those used for measurements of 90Y-ibritumomab tiuxetan (ZEVALIN). The radioactivity concentration of test-samples was verified by the US National Institute of Standards and Technology. Forty-five results were reported by 10 participants. Eighty percent of reported values were within the US Pharmacopoeia content standard (+/-10%) for 90Y-ZEVALIN. All results were within US Nuclear Regulatory Commission conformance limits (+/-20%) for defining therapeutic misadministrations.
authors.affiliation: The National Institute of Standards and Technology, Nuclear Medicine Standards Program, 100 Bureau Drive, MS 8462, Gaithersburg, MD 20899, USA. michael-schultz@uiowa.edu
authors.forename: Michael K
authors.initials: MK
authors.lastname: Schultz
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Cessna
authors.forename: Tamara L
authors.initials: TL
authors.lastname: Anderson
authors.forename: James A
authors.initials: JA
authors.lastname: Ponto
authors.forename: Neil
authors.initials: N
authors.lastname: Petry
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Kowalsky
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Palmer
authors.forename: Uwe F
authors.initials: UF
authors.lastname: Beinlich
authors.forename: William
authors.initials: W
authors.lastname: Baker
authors.forename: George H
authors.initials: GH
authors.lastname: Hinkle
authors.forename: Joseph C
authors.initials: JC
authors.lastname: Hung
authors.forename: Timothy
authors.initials: T
authors.lastname: Quinton
authors.forename: Peter A
authors.initials: PA
authors.lastname: Rice
authors.forename: Chaitanya
authors.initials: C
authors.lastname: Divgi
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Norenberg
mesh_terms: D000554:Ambulatory Care Facilities / Q000592:standards; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy; D009683:Nuclear Medicine / Q000592:standards; D010594:Pharmacies / Q000592:standards; D010865:Pilot Projects; D011786:Quality Control; D016499:Radioimmunotherapy; D011874:Radiometry / Q000379:methods / Q000592:standards; D019275:Radiopharmaceuticals / Q000032:analysis* / Q000592:standards / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012015:Reference Standards; D014481:United States; D015021:Yttrium Radioisotopes / Q000032:analysis* / Q000592:standards / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan